2 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Recurrent Histiocytic and Dendritic Cell Neoplasm: new trials by email Literature Review of Recurrent Histiocytic and Dendritic Cell Neoplasm trials Research Report on Recurrent Histiocytic and Dendritic Cell Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
Lymphoma, Non-Hodgkin (3) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Medulloblastoma (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Sarcoma, Ewing (2) · Wilms Tumor (2) · Brain Neoplasms (1)
Hemic and Lymphatic Diseases (4) · Lymphatic Diseases (4) · Neoplasms (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lung Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Histiocytosis (2)
130-nm albumin-bound paclitaxel (1) · Cetuximab (1) · Gemcitabine (1) · IFL protocol (1) · Magnetic Resonance Spectroscopy (1) · Nuclear Medicine Department, Hospital (1) · Panitumumab (1) · Phantoms, Imaging (1) · Pharmacogenomic Variants (1) · X-Rays (1) · choline salicylate (1) · selinexor (1) · selpercatinib (1) · ulixertinib (1)
National Cancer Institute (NCI) (2) · Institut de Recherches Internationales Servier (1) · Mayo Clinic (1)
United States (4) · Australia (2) · Puerto Rico (2) · China (1) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Andrea T Franson (1) · Jonas Paludo, MD (1) · Kieuhoa T Vo (1)
PMID 31401903, PMID 38935895, PMID 42867148
U10CA180886 (2), 2025 (1), P50CA097274 (1)